Advertisement
Advertisement
U.S. markets open in 43 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Arcturus Therapeutics Holdings Inc. (ARCT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
17.33-0.34 (-1.92%)
At close: 04:00PM EST
17.33 0.00 (0.00%)
After hours: 04:01PM EST
Advertisement

Arcturus Therapeutics Holdings Inc.

10628 Science Center Drive
Suite 250
San Diego, CA 92121
United States
858 900 2660
https://arcturusrx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees177

Key Executives

NameTitlePayExercisedYear Born
Mr. Joseph E. Payne M.Sc.Founder, Pres, CEO & Director960kN/A1972
Dr. Padmanabh ChivukulaFounder, Chief Scientific Officer, COO & Sec.750kN/A1979
Mr. Andrew H. Sassine MBACFO & Director750kN/A1964
Mr. Lance KurataChief Legal Officer560kN/AN/A
Dr. Steven George Hughes M.B.A., M.D.Strategic Clinical Advisor & Member of Scientific Advisory Board644kN/A1968
Mr. Keith C. Kummerfeld CPAVP of Fin. & Corp. ControllerN/AN/AN/A
Dr. Dushyant B. Varshney Ph.D.Exec. VP & Chief Technology OfficerN/AN/AN/A
Mr. Deepankar RoySr. Director of Investor RelationsN/AN/AN/A
Kyle GutstadtSr. Analyst of Investor & PRN/AN/AN/A
Mr. Kevin T. SkolSr. VP of Bus. Devel. & Alliance ManagementN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.

Corporate Governance

Arcturus Therapeutics Holdings Inc.’s ISS Governance QualityScore as of December 1, 2022 is 6. The pillar scores are Audit: 9; Board: 6; Shareholder Rights: 7; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement